

Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome, Transient Ischemic Attack, and Noncardioembolic Stroke in an Era of Cost Containment

Chad Kessler, MD, MHPE, FACEP,*†‡ Kurian Thomas, MD,§ and John Kao, MD||

Abstract: Physicians are aware of the profound impact of oral antiplatelet therapy for secondary prevention of acute coronary syndrome (ACS), transient ischemic attack, and noncardioembolic stroke. Numerous clinical studies have compared the benefits of aspirin (ASA) alone with those of combination therapy with extended-release dipyridamole or with those of clopidogrel, with or without ASA, for secondary stroke prevention; and of ASA monotherapy compared with ASA plus clopidogrel combination therapy for secondary prevention in various ACS populations. More recently, ASA plus prasugrel has been compared with ASA plus clopidogrel in a high-risk ACS population. However, given the different treatment modalities and methods used in the various trials, it is difficult to make generalizations as to which therapy is most effective with the lowest risk of bleeding. Further complicating physician's decision making are cost considerations, particularly with the newer oral antiplatelet agents, which are considerably more expensive than ASA. This review provides a brief overview of the clinical data on each of the currently marketed oral antiplatelet agents and the available data on cost-effectiveness for the secondary prevention of ACS, transient ischemic attack, and noncardioembolic stroke.

Key Words: anticoagulants, stroke, angina, myocardial infarction, cost-benefit analysis

(*J Investig Med* 2012;60: 792–800)

Coronary heart disease (CHD) and stroke remain the first and third leading causes of mortality in the United States, respectively, and the first and second leading causes of deaths worldwide, respectively.^{1,2}

The economic costs of CHD and stroke are enormous, with an anticipated cost of \$250.8 billion in direct and indirect costs for both in 2010 in the United States.³

In the United States, an estimated 1.37 million hospitalizations for acute coronary syndromes (ACSs) occurred in 2006, more than half (810,000) of which were for myocardial infarction

(MI), and 537,000 of which were for unstable angina.³ Direct medical costs of ACS are estimated at approximately \$75 billion annually, with much of that attributed to inpatient costs. The costs are not limited to a Medicare population; an analysis of costs in a younger managed care population with new-onset ACS identified total health care costs of \$309 million, or \$22,529 per patient, for an mean follow-up of 292 days after hospitalization or care provided in an emergency department.⁴ Overall, medical costs during the first year after a stroke are more than 10 times the cost of the average commercially insured individual.⁵

Although death rates for CHD, including MI, have fallen in the past 40 years, owing in part to significant improvements in treatments and in primary and secondary prevention approaches, the mortality rate is likely to plateau or even rise, given the concurrent epidemics of obesity and diabetes.^{1,6} This makes continued improvements in prevention critical.

The incidence and severity of stroke in the United States have also decreased in recent years, also likely owing to improved detection and treatment as well as to early identification of transient ischemic attack (TIA).⁷ However, stroke still carries an extremely high mortality rate of 41.6%, with 133,900 deaths in 2007.¹ The mortality rate is highest for hemorrhagic strokes, with 37% to 38% of these strokes resulting in death within 30 days among individuals aged 45 to 64 years, compared with 8% to 12% of ischemic strokes.¹ The 1-month mortality rate for ischemic stroke among individuals aged 65 years or older is 8.1%, whereas the rate for hemorrhagic stroke is 44.6%.²

Significant opportunities for secondary stroke prevention remain, particularly because approximately half of all strokes that occur in the first week after a TIA occur within the first 24 hours.⁸ Appropriate treatment after TIA or stroke could significantly reduce the risk of stroke and its attendant disability and direct and indirect costs.^{5,9}

This review provides an overview of major cardiac and stroke trials, which also have separate published papers with economic analyses of their data. We summarize the major antiplatelet agents and the pivotal trials used in their approval for secondary prevention of cardiovascular disease as a foundation for the economic discussion. Clinical effectiveness of these agents is then modeled to project cost-effectiveness. The economic models vary, making comparisons between studies difficult. By presenting a variety of papers, an overall picture of these agents emerges.

THE ROLE OF ORAL ANTIPLATELET THERAPY IN SECONDARY PREVENTION OF ACS, TIA, AND NONCARDIOEMBOLIC STROKE

Oral antiplatelet therapy is a critical component of secondary prevention of ACS, TIA, and noncardioembolic stroke. Currently, 5 oral antiplatelet therapies are available in the US market: aspirin (ASA), combination therapy with extended-release (ER) dipyridamole plus ASA, ticlopidine, clopidogrel, and prasugrel.

From the Departments of *Internal Medicine and †Emergency Medicine, University of Illinois-Chicago; Departments of ‡Emergency Medicine, §Neurology, and ||Cardiology Service, Jesse Brown VA Hospital, Chicago, IL. Received September 23, 2011, and in revised form February 1, 2012. Accepted for publication February 1, 2012.

Reprints: Chad Kessler, MD, FACEP, FAAEM, Department of Emergency Medicine, Jesse Brown Veteran's Administration Medical Hospital, 1449 S Peoria St, Chicago, IL 60608. E-mail: Chad.Kessler@va.gov. A portion of this work was supported by Boehringer-Ingelheim Pharmaceuticals, Inc (BIP).

The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors and are fully responsible for all content and editorial decisions, and they were involved in all stages of manuscript development. The authors received no compensation related to the development of the manuscript.

Copyright © 2012 by The American Federation for Medical Research
ISSN: 1081-5589

DOI: 10.2310/JIM.0b013e31824e9a50

Current American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend the use of dual antiplatelet therapy with ASA and clopidogrel for all patients with ACS. Although ticlopidine is included in the guidelines, it is rarely used in the United States owing to the high incidence of drug-related hematologic abnormalities.¹⁰ In patients who have had a stroke or TIA, ASA alone or in combination with ER dipyridamole, or clopidogrel, is recommended.^{11,12}

The basis for these recommendations is outlined below.

Aspirin

Aspirin selectively and irreversibly inhibits arachidonate cyclooxygenase in platelets, limiting the generation of thromboxane A₂, a key mediator of platelet activation and aggregation. Aspirin has been a mainstay of antiplatelet therapy in both ACS and stroke since the Antiplatelet Trialists' Collaboration demonstrated that it reduced the relative risk of vascular deaths and nonfatal MI.¹³ Today, major guidelines recommend its use for secondary prevention in both patients with ACS and patients with a risk of recurrent stroke or other vascular events.¹⁴⁻¹⁶

A meta-analysis of data from clinical trials, examining the impact of ASA on the risk of serious vascular events and major bleeds in stroke, found that ASA increased the number of major bleeding episodes, both gastrointestinal and extracranial.¹⁷ Therefore, although ASA is exceptionally inexpensive, the bleeding risk must be taken into account based on patients' medical history.

ER Dipyridamole Plus ASA

Dipyridamole inhibits platelet function through several biochemical pathways that ultimately increase platelet cyclic adenosine monophosphate and inhibits cyclic guanosine monophosphate phosphodiesterase, thereby increasing cyclic guanosine monophosphate phosphodiesterase levels.¹⁸ Extended-release dipyridamole plus ASA is indicated to reduce the risk of stroke in patients who have had a TIA or ischemic stroke due to thrombosis.¹⁸ It has not been specifically studied in patients with ACS or MI, although some patients in the stroke trials have a history of MI.

The trial leading to the approval of this combination therapy, Second European Stroke Prevention Study, compared ASA plus ER dipyridamole with either compound alone or with placebo in preventing the primary end points of stroke or death, or of a composite of stroke and death, over 2 years in patients with prior TIA or stroke.

In the study population of 6602 patients, the combination reduced the risk of stroke or death by 24% versus placebo compared with a 13% reduction with ASA alone and a 15% reduction with dipyridamole alone compared with placebo. However, the treatment had no statistically significant effect on all-cause mortality. The most common adverse effect in both groups receiving dipyridamole was headache, whereas all-site and gastrointestinal bleeding were more common in patients receiving ASA than in those receiving dipyridamole.¹⁹

In the Prevention Regimen for Effectively Avoiding Second Strokes trial, the combination of ASA plus ER dipyridamole was associated with a reduction in the risk of recurrent stroke of similar magnitude to that for clopidogrel. However, the trial was not sufficiently powered to demonstrate superiority or equivalence of either drug. Although more hemorrhagic strokes occurred in the ER dipyridamole plus ASA group than in the clopidogrel group, the net risk for recurrent stroke or major hemorrhagic event was similar and there was no significant difference in the risk of fatal or disabling stroke. More patients permanently discontinued the ASA plus ER

dipyridamole treatment than discontinued the clopidogrel treatment because of adverse events, primarily headache, vomiting, and nausea.²⁰ The combination of ER dipyridamole plus ASA has not been evaluated in patients with ACS.

Although these 2 important trials have demonstrated the effectiveness of combination therapy in stroke prevention, some patients cannot tolerate dipyridamole and the addition of this medication is more cost-prohibitive than ASA alone.

Clopidogrel

Clopidogrel is a prodrug that requires first-pass metabolism in the liver to its active metabolites to exert its antiplatelet effects via inhibition of the P2Y₁₂ adenosine diphosphate receptor.²¹ It is indicated for the reduction of thrombotic events in patients with recent MI, recent stroke, and established peripheral arterial disease (PAD). In patients with ACS, clopidogrel is indicated in all patients with ST-elevation myocardial infarction (STEMI) who receive a stent and all patients with non-ST-elevation myocardial infarction (NSTEMI) with or without stent placement.²² In March 2010, the US Food and Drug Administration announced the addition of a boxed warning to the label of clopidogrel regarding the drug's reduced effectiveness in patients who are poor metabolizers of the drug due to genetic differences in CYP2C19 function.²³

In the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events trial, clopidogrel alone was compared with ASA alone in reducing the risk of ischemic stroke, myocardial infarction, or death from cardiovascular causes in patients with PAD, a recent stroke, or myocardial infarction. The relative risk reduction was 8.7% in favor of clopidogrel.²⁴ Subgroup analysis of the trial demonstrated that clopidogrel's effectiveness differed according to the specific vascular bed affected. A nonsignificant improvement over ASA occurred in patients with stroke and MI. The greatest benefit was in the subset of patients who had PAD.

Only one trial has specifically evaluated the use of clopidogrel plus ASA or placebo in patients who had stroke. It examined the incremental effect of ASA versus placebo in patients with prior stroke treated with clopidogrel. The Management of Atherothrombosis with Clopidogrel in High-risk Patients With Recent TIA or Ischemic Stroke trial randomized patients with recent stroke or TIA and at least one other vascular event who were already receiving clopidogrel to receive additional ASA or placebo for 18 months' follow-up.²⁵ The primary end point was a composite of stroke, MI, vascular death, or rehospitalization for acute ischemia. Results did not differ significantly between groups. The patients receiving ASA had a higher rate of life-threatening bleeding episodes.²⁵ Thus, although there was no significant difference in the ability of ASA added to clopidogrel to reduce major vascular events, the combination did significantly increase the risk of serious bleeding.

Evidence in support of the use of clopidogrel plus ASA in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) comes from numerous clinical trials²⁶⁻³¹; however, only Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) is discussed. The CURE trial randomly assigned a little more than 12,000 patients with NSTEMI ACS who presented within 24 hours of symptom onset to receive clopidogrel, 300 mg, immediately, then either clopidogrel (75 mg)/ASA or placebo/ASA for 3 to 12 months. Patients in the clopidogrel group demonstrated a 20% relative risk reduction in the composite primary outcome of death from cardiovascular causes, nonfatal MI, or stroke compared with those in the ASA/placebo group.³² PCI-CURE evaluated patients with NSTEMI ACS undergoing PCI in the CURE trial.

TABLE 1. Economic Analyses of Antiplatelet Therapy for Secondary Prevention in Patients With ACS or Stable Cardiovascular Disease

| Study/Country/Analysis Time Period/Sensitivity Analysis | Source of Clinical Data | Cost Perspective | Cost-Effectiveness of Clopidogrel |
|--|--|---|---|
| Badia et al. ³⁹ (2005) -Lifetime: €30,000 per LYG -Spain -12 months and lifetime analysis period -Outer limits of 95% CI of the relative risk of events | CURE (clopidogrel + ASA vs ASA) | N/A | -12 months: €17,190 per LYG -Clopidogrel added to standard therapy in the first year of treatment is cost-effective |
| Beinart et al. ⁴⁰ (2005) -US -12-month period -Bootstrap method (5000 iterations) | CREDO (ASA + clopidogrel 1 month vs ASA + clopidogrel 12 months) | Societal | -Based on Framingham life-expectancy estimation: \$3685–\$4353/LYG -Based on Saskatchewan life-expectancy estimation: \$2929–\$3460/LYG -Pretreatment with clopidogrel prior to PCI followed by 1 year of clopidogrel treatment is “highly” cost-effective. |
| Berg et al. ⁴¹ (2008) -Sweden/France/Germany -30 days and 1 year -Bootstrap analysis (1000 replications) and second-order stochastic analysis (1000 simulations) | Meta-analysis of PCI-CURE, CREDO, PCI-CLARITY (to determine effect of clopidogrel on MI and cardiovascular death at 30 days and at end of follow-up at 1 year) | Societal (Sweden) Payer (France/Germany) | -Sweden: pretreatment and long-term treatment = 0.093 QALYs -Germany: 0.090 QALYs; treatment cost €709 more than no treatment, for an ICER of €7871/QALY -France: Pretreatment and long-term treatment: 0.095 QALY. Based on direct medical costs only, incremental cost is €494 euros for clopidogrel, or an ICER of €5226/QALY -Preterm and long-term (1-year) treatment after PCI with clopidogrel are cost-effective -\$15,696/LYG -Clopidogrel treatment for 1 year after PCI is cost-effective |
| Cowper et al. ⁴² (2005) -US -12 months -Single and multiway sensitivity analysis | Patients undergoing PCI at Duke University Medical Center from January 1999 to December 2001 | Societal | |
| Gaspoz et al. ⁴³ (2002) -US -25 years -Outer limits of 95% CI of the relative risk of events based on the Antiplatelet Trial List | Coronary Heart Disease Model (clopidogrel vs ASA) | Payer | -\$11,400/QALY -Monotherapy with ASA or with clopidogrel in ASA-intolerant patients is cost-effective. However, monotherapy with clopidogrel or clopidogrel combination with ASA is not cost-effective in all patients. Combination therapy with clopidogrel and ASA is cost-effective in patients at highest risk. However, as the cost of clopidogrel declines, its cost-effectiveness increases. |
| Kamron et al. ⁴⁴ (2005) -UK -Lifetime | Observation study (clopidogrel vs ASA) | Payer | -Clopidogrel: £18,888/QALY -ASA: £21,488/QALY -Two years of treatment with clopidogrel in patients at risk of secondary occlusive vascular events is cost-effective |

| | | | |
|--|--|-----------------|--|
| <p>-Probabilistic sensitivity analysis using Monte Carlo simulations (1000 simulations) -Kolm et al.⁴⁵ (2007) -Canada -Lifetime -Bootstrap methods with 5000 replicates Cost-effectiveness threshold of \$20,000</p> | <p>CURE (clopidogrel + ASA vs ASA in NSTEMI) and PCI-CURE (clopidogrel + ASA vs ASA alone for PCI pretreatment and clopidogrel for posttreatment)</p> | <p>NA</p> | <p>-92% of bootstrap replications in CURE <\$20,000; -82.2% in PCI-CURE -ICER per event prevented = \$12,524/year/CURE; \$9250/year/PCI-CURE -ICER per life-years gained = \$3856/year/CURE \$3763/year/PCI-CURE</p> |
| <p>Lamy et al.⁴⁶ (2004) -US, UK, Sweden, France, Canada -9 months -Bootstrap analysis</p> | <p>CURE (clopidogrel + ASA vs ASA)</p> | <p>Societal</p> | <p>-Clopidogrel plus ASA is cost-effective compared with ASA alone and with other commonly used cardiovascular therapies -US: €25,437 per prevented life-threatening event -UK: €16,847 per prevented life-threatening event -Sweden: €13,857 per prevented life-threatening event -France: €16,186 per prevented life-threatening event -Canada: €5585 per prevented life-threatening event -Overall 2% absolute reduction in total primary events resulted in significant incremental cost-effectiveness ratio similar to those of other antiplatelet options -Average cost of management: -ASA: \$10,940 -ASA + clopidogrel: \$10,757 -The overall cost impact of clopidogrel plus ASA was similar to that of ASA monotherapy</p> |
| <p>Lee et al.⁴⁷ (2006) -Hong Kong -10 months</p> | <p>Retrospective case review, 54 patients treated with ASA alone compared with hypothetical cohort treated with clopidogrel + ASA</p> | <p>Payer</p> | <p>-ASA + clopidogrel: \$10,757 -The overall cost impact of clopidogrel plus ASA was similar to that of ASA monotherapy</p> |
| <p>Lindgren et al.⁴⁸ (2004) -Sweden -12 months -Outer limits of 95% CI of the relative risk of events</p> | <p>CURE (clopidogrel + ASA vs ASA)</p> | <p>Societal</p> | <p>-€1009-€1365 per LYG -Clopidogrel plus ASA “standard therapy,” including ASA, is cost-effective</p> |
| <p>Mahoney et al.⁴⁹ (2006) -Early PCI subgroup: \$935/LYG -US -12 months</p> | <p>PCI-CURE (clopidogrel + ASA vs ASA) Considered the impact of clopidogrel on risk of fatal MI only, fatal and nonfatal MI only, and all death</p> | <p>Societal</p> | <p>-Overall: \$2856-\$4885/LYG -Clopidogrel given for up to 1 year after PCI in patients with ACS is a “highly cost-effective treatment strategy” -Prasugrel treatment would reduce costs by \$221 per patient and increase life expectancy by 0.012</p> |
| <p>Mahoney et al.⁵⁰ (2010) -US -14.7 months -Bootstrap resampling</p> | <p>TRITON-TIMI 38 (prasugrel vs clopidogrel in moderate-to-high-risk ACS patients undergoing PCI)</p> | <p>Societal</p> | <p>-At an estimated generic price point for clopidogrel of \$1/day, prasugrel was cost-saving over the first 30 days only -€3022/LYG</p> |
| <p>Ringborg et al.⁵¹ (2005) -Sweden -12 months -Probabilistic sensitivity analysis using Monte Carlo simulation (1000 simulations)</p> | <p>CREDO (ASA + clopidogrel 1 month vs ASA + clopidogrel 12 months)</p> | <p>Societal</p> | <p>-Long-term treatment (12 months) with clopidogrel plus ASA after PCI is cost-effective compared with 28-day therapy</p> |

(continued on next page)

TABLE 1. (Continued)

| Study/Country/Analysis Time Period/Sensitivity Analysis | Source of Clinical Data | Cost Perspective | Cost-Effectiveness of Clopidogrel |
|---|---------------------------------|------------------|---|
| Schleinitz and Heidenreich ⁵² (2005) | CURE (clopidogrel + ASA vs ASA) | Societal | -\$15,400/QALY -1 year of clopidogrel plus ASA in high-risk ACS patients is cost-effective compared with ASA alone |
| -US | | | |
| -Lifetime | | | |
| -Probabilistic sensitivity analysis using Monte Carlo simulation (1000 simulations) | | | |
| Weintraub et al. ⁵³ (2005) | CURE (clopidogrel + ASA vs ASA) | Payer | -\$6318/LYG -Clopidogrel was cost-effective option for patients with ACS |
| -US | | | |
| -9 months | | | |
| -Bootstrap methods (5000 replicates) | | | |

Parts of this table were reproduced with permission from Cheng.⁵⁴
CAPRIE indicates Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events; CI, confidence interval; CREDO, Clopidogrel for the Reduction of Events During Observation; ESPS-2, Second European Stroke Prevention Study; ICER, incremental cost-effectiveness ratio; LYG, life years gained; PCI-CLARITY, Percutaneous Coronary Intervention in the Clopidogrel as Adjunctive Reperfusion Therapy; QALY, quality-adjusted life years.

Pretreatment with clopidogrel and ASA before PCI followed by long-term (mean of 8 months) clopidogrel reduced the relative risk of the primary end point of a composite of cardiovascular death, MI, or urgent target-vessel revascularization within 30 days of PCI by 30% compared with ASA plus placebo.³³ Clopidogrel will have a generic formulation in the United States beginning in 2012. How this will affect cost-effectiveness in recurrent stroke prevention remains to be seen. A press release from Astra-Zeneca using European Union labeling of ticagrelor and generic clopidogrel showed a cost-effective gain in quality-adjusted life year in favor of ticagrelor for patients with ACS. Data for this economic substudy were derived from the PLATElet inhibition and patient Outcomes trial.³⁴

Prasugrel

Prasugrel is a thienopyridine analog with a similar mechanism of action to clopidogrel, irreversibly inhibiting the binding of adenosine diphosphate receptors to platelets, preventing their activation and reducing platelet aggregation.³⁵ It is indicated for reduction of thrombotic events in patients with ACS who are to undergo PCI.³⁶ The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 compared clopidogrel with prasugrel in patients with moderate- to high-risk ACS who were scheduled to undergo PCI. The primary efficacy end point was composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke. In the cohort of patients with STEMI alone, the rate of the primary efficacy end point was reduced in favor of prasugrel. In the overall cohort of patients with ACS, greater efficacy of prasugrel came from the reduction in MI in the prasugrel group compared with the clopidogrel group.³⁰

However, patients with a previous cerebrovascular event before enrollment in the trial had numerically worse clinical outcomes based on the primary end point, and more frequent bleeding (including intracranial bleeding) than those without a previous cerebrovascular event.³⁰ Prasugrel carries a black box warning of bleeding risk.³⁶ Individuals with a history of TIA or stroke should not receive prasugrel.

Ticagrelor

Ticagrelor is an oral antiplatelet that reversibly binds to adenosine diphosphate receptor P2Y₁₂, with evidence of a faster onset and greater platelet aggregation inhibition than that seen with clopidogrel. The PLATElet inhibition and patient Outcomes study compared ticagrelor plus ASA with clopidogrel plus ASA in patients with ACS.³⁷

At 12 months, the ticagrelor group demonstrated a 16% relative risk reduction in the primary end point of a composite of death from vascular causes, MI, or stroke (864/9333 end points in the ticagrelor group vs 1014/9291 in the clopidogrel group). Ticagrelor also proved more effective at preventing MI alone and death from other vascular causes but not in preventing stroke alone. There was no significant difference in rates of serious bleeding between the 2 groups, although the ticagrelor group experienced a higher rate of noncoronary artery bypass graft-related major bleeding.³⁸

ECONOMIC ANALYSES OF COST-EFFECTIVENESS OF ANTIPLATELET THERAPY FOR ACS AND SECONDARY STROKE PREVENTION

Given the current economic climate and the increased pressure from payers for efficacy as well as cost-effectiveness

in health care, there is a critical need to identify the most cost-effective approaches, whether for treatment or prevention. Although clinical guidelines provide important recommendations regarding treatment modalities, they rarely consider specific costs. Guidelines from the AHA, American Stroke Association (ASA), and the American College of Chest Physicians (ACCP) make few distinctions between the use of ASA with or without ER dipyridamole or clopidogrel in their recommendations for post-TIA/stroke oral antiplatelet therapy. The ACCP guidelines recommend ASA either alone or with ER dipyridamole, or clopidogrel for initial therapy in patients who experienced an ischemic stroke or TIA. They further recommend ER dipyridamole/ASA over ASA alone and clopidogrel over ASA alone based on cost, tolerability, availability, ease of use, and absolute risk. In addition, whereas the AHA/ASA recommendations make no distinction between ASA monotherapy, combination therapy with ER dipyridamole, or clopidogrel monotherapy, they do note the in-

fluence that adverse effects, cost, and comorbid illnesses should play in drug selection.^{11,12}

Although numerous economic analyses have been conducted on the various antiplatelet agents (Tables 1 and 2), such studies vary widely in their assumptions and models, making comparisons across studies challenging. Tables 1 and 2 provide economic analysis of the major studies used in this paper. Table 1 is focused on cardiac protocols (CURE, Clopidogrel for the Reduction of Events During Observation, etc.), whereas Table 2 is focused on stroke/vascular studies (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events, Second European Stroke Prevention Study, etc.). Rather than evaluating actual costs and usage, most project data through various simulations.⁶⁰ This requires that they be evaluated individually based on their quality rather than compared with one another.⁶⁰ Another limitation to such studies is that the cost of the drug varies significantly depending on the patients' geographic location and insurance program. A factor that

TABLE 2. Economic Analyses of Antiplatelet Therapy for Prevention of Stroke/Vascular Events

| Study/Country/Analysis Time Period/Sensitivity Analysis | Source of Clinical Data | Cost Perspective | Cost-Effectiveness of Antiplatelet Agents |
|---|---|------------------|--|
| Chambers et al. ⁵⁵ (1999) -UK -5 years -Univariate sensitivity analyses | ESPS-2 (ER dipyridamole 400 mg/d + ASA 50 mg/d vs ASA, dipyridamole, or placebo only) | Societal | Combination prevented 29 more strokes than ASA alone per 1000 patients, at an additional cost of £1900 (1996 values). Cost effectiveness did not exceed £7000 per stroke averted or £11,000 pounds per QALY gained. "The extra costs of treatment are balanced by the savings in future costs of acute care and long-term care of the disabled." |
| Karnon et al. ⁴⁴ (2005) -UK -2 years -Probabilistic sensitivity analysis using Monte Carlo simulations (1000 simulations) | CAPRIE (clopidogrel for 2 years followed by ASA for lifetime, or ASA alone) | Payer | -\$18,888 /LYG -\$21,489/QALY -Clopidogrel is cost-effective in patients at risk of secondary occlusive vascular events |
| Marissal et al. ⁵⁶ (2004) -France -2 years -Probabilistic sensitivity analysis using Monte Carlo simulations | ESPS-2 (ASA 50 mg + dipyridamole 400 mg vs ASA alone) | Societal | ASA + dipyridamole: net benefits per avoided stroke recurrence of \$23,932 compared with ASA alone, and of \$31,555 compared with dipyridamole alone ER dipyridamole/ASA is cost-effective compared with ASA alone and dipyridamole alone |
| Sarasin et al. ⁵⁷ (2000) -US -Lifetime | Hypothetical cohort of high-risk patients 65+ years, based on results of CAPRIE and ESPS-2 (clopidogrel 75 mg/d, ASA 325 mg/d or dipyridamole 400 mg/d + ASA, 50 mg/d) High-risk patients 65+ years | Societal | Clopidogrel: ICER <\$50,000 up to age 80* \$30,000/QALY (ages 65 or 70 years with cost <\$3.80) -Clopidogrel vs ASA: ICER >\$50,000 -ASA + dipyridamole: greater cost-effectiveness and efficacy than ASA alone (was not compared directly with clopidogrel) |
| Schleinitz et al. ⁵⁸ (2004) -US -3 years -Probabilistic sensitivity analyses at the extremes of the 95% CI for each model input -Probabilistic sensitivity analysis using Monte Carlo simulations (1000 simulations) | CAPRIE (ASA vs clopidogrel) | Societal | -PAD: 0.55 QALY increase with clopidogrel; \$25,100/QALY -Poststroke: 0.17 QALY increase with clopidogrel \$31,200/QALY -Post-MI: 0.26 QALY decrease with clopidogrel -In conclusion, clopidogrel is cost-effective and provides a substantial increase in quality-adjusted life expectancy. |
| Shah and Gondek ⁵⁹ (2000) -US -2 years after stroke | ESPS-2 (ASA vs clopidogrel vs ASA/dipyridamole) | N/A | -Cost per stroke averted: Clopidogrel: \$161,316; ASA/ER-dipyridamole: \$28,472 -ER dipyridamole/ASA is cost-effective compared with ASA monotherapy |

*Results highly sensitive to cost of clopidogrel.

may alter prescribing habits is that clopidogrel was set to lose its patent protection in the United States in November 2011, which will significantly change the cost-effectiveness results.⁶¹

Meta-analyses may be beneficial in evaluating cost-effectiveness. In one meta-analysis of 21 studies, Heeg et al.⁶² concluded that “from a purely cost effectiveness” perspective, ASA was always the cheapest, safest, and most effective treatment for the secondary prevention of cardiovascular events, although in higher-risk patients, clopidogrel for 1 or 2 years, either alone or with ASA, was more cost-effective for secondary prevention of ischemic events.⁶³ Using data from both MI and stroke studies, they also concluded that the combination of ASA and ER dipyridamole for secondary stroke prevention was more cost-effective than ASA alone and, in indirect comparisons, than clopidogrel.⁶²

The authors concluded that “the cost-effectiveness of antiplatelets hinges on the patient’s initial risk, the risk reduction associated with treatment, and the price of the treatment Cost-effectiveness of antiplatelets can be optimized by individualizing the treatment decision based on patient risk and expected risk reduction.”⁶²

It may also be helpful to consider economic analyses used to determine national health plan coverage, such as that of Great Britain. National data from Great Britain compared ASA, ER dipyridamole, and ER dipyridamole plus ASA for the prevention of recurrent stroke, determining that the combination therapy would likely result in “significant health benefits at modest extra costs to health and social services” in the prevention of further stroke and other vascular events when compared with ASA alone, and that dipyridamole alone also seems to be a cost-effective alternative to no treatment in patients who cannot tolerate ASA.⁵⁶

Based on this analysis, Britain’s National Institute of Clinical Excellence (NICE), which considers cost-effectiveness in making its recommendations, recommends that ER dipyridamole plus ASA be used as part of the prevention of occlusive vascular events for up to 2 years after an initial ischemic stroke or TIA, followed by long-term treatment with ASA. The NICE also recommends clopidogrel alone as part of prevention of occlusive vascular events in patients who cannot tolerate ASA and who have experienced either an occlusive vascular event or who have symptomatic PAD.⁶³

Cheng⁵⁴ reviewed multiple cost-effectiveness studies on the use of clopidogrel for secondary prevention of cardiovascular events. She found that in all patients with NSTEMI and in those who received coronary stents, treatment with the drug was cost-effective when used in addition to ASA therapy for up to 12 months.⁵⁴ However, it was cost-effective when used for secondary prevention of coronary artery disease only in patients unable to tolerate ASA therapy. The studies she used in her analysis are included in Table 1.

MISSED OPPORTUNITIES IN ACS AND STROKE PREVENTION

Decades of clinical research and pharmaceutical development have resulted in numerous evidence-based recommendations related to the prevention of secondary cardiovascular, cerebrovascular, and peripheral vascular events.^{12,64} Yet, as Mosca et al.⁶⁵ and Kumar et al.⁶⁶ have found, physician’s awareness and implementation of national guidelines vary considerably based on physician’s specialty, the specific guidelines, patient risk level, and geographic location. For instance, although all major medical organizations recommend the use of antiplatelet agents for patients with ACS, Etamad and McCollam⁴ found that the use of antiplatelet therapy in patients after a primary ACS event in a

managed care population was only 36%. This was from a retrospective claims analysis of patients from 1999 to 2001. In the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines trial, which evaluated the care provided to 64,775 patients with NSTEMI ACS treated at 350 US hospitals, up to 25% of opportunities to provide guideline-recommended care were missed, particularly the provision of recommended antiplatelet therapy. The authors concluded that a lack of guideline adherence significantly contributed to the rate of in-hospital mortality.⁶⁷

The situation is not much better in patients who had stroke, with studies finding adherence rates as low as 53% for antithrombotic therapy.⁶⁸ As one researcher wrote in an article evaluating prevention efforts in stroke, “. . . where data are available, all primary and secondary stroke prevention efforts are underused and identify clear areas for improvement.”⁶⁸ Implementing evidence-based guidelines for stroke and ACS, by contrast, can significantly reduce morbidity and mortality and may reduce costs as well.⁶⁹

CONCLUSION

Acute coronary syndrome and stroke account for most deaths in the United States and worldwide and result in significant morbidity as well as direct and indirect economic costs. A cornerstone of secondary prevention is the appropriate use of oral antiplatelet therapies. Because several efficacious oral therapies are available, the decision of which to use often depends on physician’s preference and patient risk factors. The guidelines do not take into account patient costs, geographical considerations, or compliance. It has become increasingly clear that there is not an easy clinical decision rule that can be applied to all patients requiring secondary prevention of ACS, TIA, or stroke. Physicians need to continue to educate themselves on all aspects of health care that may have an effect on patients, including patient compliance, which in turn is often affected by a medication’s expense. In this health care environment in which cost-effectiveness trails just behind clinical effectiveness in importance, it is critical that physicians become aware of and consider the economic ramifications of the medication choices they recommend to their patients.

ACKNOWLEDGMENTS

Writing and editorial assistance was provided by Debra Gordon, MS, of Publication CONNEXION, which was contracted by BIPI for these services.

REFERENCES

- Lloyd-Jones DR, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2009;119(3):e21–e181.
- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med*. 2006;3(11):2011–2030.
- Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update. A report from the American Heart Association. *Circulation*. 2010;121(7):e46–e215.
- Etamad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. *J Manag Care Pharm*. 2005;11(4):300–306.
- Fitch KF, Iwasaki K, Pyenson B. Milliman Client Report. Cost impact to payers and employers of TIA and stroke: an actuarial analysis. Milliman: New York; 2008. Available at <http://publications.milliman.com>.

- com/research/health-rr/pdfs/cost-impact-payers-employers-rr11-01-08.pdf. Accessed June 15, 2011.
6. Ford ES, Ajani US, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. *N Engl J Med*. 2007;356(23):2388–2398.
 7. Carandang RS, Seshadri S, Beiser A, et al. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. *JAMA*. 2006;296(24):2939–2946.
 8. Chandratheva AZ, Mehta Z, Geraghty OC, et al; on behalf of the Oxford Vascular Study. Population-based study of risk and predictors of stroke in the first few hours after a TIA. *Neurology*. 2009;72(22):1941–1947.
 9. Wu CM, Manns BJ, Hill MD, et al. Rapid evaluation after high-risk TIA is associated with lower stroke risk. *Can J Neurol Sci*. 2009;36(4):450–455.
 10. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. *N Engl J Med*. 2000;342(24):1773–1777.
 11. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). *Chest*. 2008;133(6 suppl):630S–669S.
 12. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. *Stroke*. 2008;39(5):1647–1652.
 13. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. *BMJ*. 1994;308(6921):81–106.
 14. Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). *Chest*. 2008;133(6 suppl):776S–814S.
 15. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons; endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *Circulation*. 2007;116(7):e148–e304.
 16. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. *Circulation*. 2008;117(2):296–329.
 17. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*. 2009;373(9678):1849–1860.
 18. Malinin AI, Eisert RM, Atar D, et al. Aggrenox® (extended-release dipyridamole and low-dose aspirin in combination): protecting platelets from excessive activation in patients with vascular events. *Heart Drug*. 2002;2:93–104.
 19. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci*. 1996;143(1):1–13.
 20. Sacco RL, Diener HC, Yusuf S, et al; PROFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med*. 2008;359(12):1238–1251.
 21. Savi P, Nurden P, Nurden AT, et al. Clopidogrel: a review of its mechanism of action. *Platelets*. 1998;9(3–4):251–255.
 22. Plavix [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals; 2009.
 23. Food and Drug Administration. Plavix (clopidogrel): Reduced effectiveness in patients who are poor metabolizers of the drug. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm204256.htm?sms_ss=email. Published March 12, 2010. Accessed June 15, 2011.
 24. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet*. 1996;348(9038):1329–1339.
 25. Diener HC, Bogousslavsky J, Brass LM, et al; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet*. 2004;364(9431):331–337.
 26. Steinhilber SR, Berger PB, Mann JT III, et al; for the CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA*. 2002;288(19):11–20.
 27. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006;354:1706–1717.
 28. Chen ZM, Jiang IX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*. 2005;366:1607–1611.
 29. Sabatine MS, Cannon CP, Gibson CM, et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med*. 2005;352(12):1179–1189.
 30. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357(20):2001–2015.
 31. Sabatine MS, Cannon CP, Gibson CM, et al; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)—Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. *JAMA*. 2005;294(10):1224–1232.
 32. Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med*. 2001;345(7):494–502.
 33. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet*. 2008;358(9281):527–533.
 34. AstraZeneca press release 'Ticagrelor more cost effective over generic clopidogrel.' May 9, 2011.
 35. Koo MH, Nawarskas JJ, Frishman WH. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease. *Cardiol Rev*. 2008;16(6):314–318.

36. Effient [package insert]. Indianapolis, IN: Eli Lilly & Co; 2009.
37. AstraZeneca Submits US New Drug Application For Ticagrelor (BRILINTA (tm), An Investigational Antiplatelet Agent. *Medical News Today*. November 22, 2009. Available at: <http://www.medicalnewstoday.com/articles/171785.php>. Accessed July 12, 2010.
38. Wallentin L, Becker RC. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361(11):1045–1057.
39. Badia X, Bueno H, Janatey JRG, et al. Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain. *Rev Esp Cardiol*. 2005;58(12):1385–1395.
40. Beinart SC, Kolm P, Veledar E, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. *J Am Coll Cardiol*. 2005;46(5):761–769.
41. Berg J, Fidan D, Lindgren P. Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO, and PCI-CLARITY trials. *Curr Med Res Opin*. 2008;24(7):2089–2101.
42. Cowper PA, Udayakumar K, Sketch MH, et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. *J Am Coll Cardiol*. 2005;45(3):369–376.
43. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. *N Engl J Med*. 2002;346(23):1800–1806.
44. Karnon J, Brennan A, Pandor A, et al. Modeling the long-term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. *Curr Med Res Opin*. 2005;21(1):101–112.
45. Kolm P, Yuan Y, Veledar E, et al. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. *Can J Cardiol*. 2007;23(13):1037–1042.
46. Lamy A, Jonsson B, Weintraub S, et al; CURE Economic Group. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. *Eur J Cardiovasc Prev Rehabil*. 2004;11(6):460–465.
47. Lee VW, Chan WK, Lee KK. A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital. *Int Heart J*. 2006;47(5):739–744.
48. Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. *J Intern Med*. 2004;255(5):562–570.
49. Mahoney EM, Mehta S, Yuan Y, et al; CURE Study Investigators. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. *Am Heart J*. 2006;151(1):219–227.
50. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel—Thrombolysis in Myocardial Infarction TRITON-TIMI 38. *Circulation*. 2010;121(1):71–79.
51. Ringborg A, Lindgren P, Johsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention. *Eur J Health Econ*. 2005;6(4):354–362.
52. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. *Ann Intern Med*. 2005;142(4):251.
53. Weintraub WS, Mahoney EM, Lamy A, et al; CURE Study Investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. *J Am Coll Cardiol*. 2005;45(6):838–845.
54. Cheng JW. Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease. *J Manag Care Pharm*. 2007;13(4):326–336.
55. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. *Pharmacoeconomics*. 1999;16(5 Pt 2):577–593.
56. Marissal J-P, Selke B, Amarencu P. Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox®/Asasantin®) in France. *Pharmacoeconomics*. 2004;22(10):661–670.
57. Sarasin FP, Gaspoz J-M, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. *Arch Intern Med*. 2000;160(18):2773–2778.
58. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. *Am J Med*. 2004;116(12):797–806.
59. Shah H, Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. *Clin Ther*. 2000;22(3):362–370.
60. Weintraub WS. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example. *J Cardiovasc Pharmacol Ther*. 2008;13(2):107–119.
61. United States Patent and Trademark Office. Available at: <http://www.uspto.gov/patents/resources/terms/156.jsp>. Last modified 3/4/2010. Accessed June 21, 2011.
62. Heeg BJ, Damen J, Van Hout B. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. *Pharmacoeconomics*. 2007;25(12):1063–1082.
63. National Institute for Health and Clinical Evidence. Clopidogrel and dipyridamole for the prevention of atherosclerotic events. May 2005. Available at: <http://www.nice.org.uk/TA090>. Accessed July 12, 2010.
64. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction). *Circulation*. 2008;118(24):2596–2648.
65. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. *Circulation*. 2005;111(4):499–510.
66. Kumar A, Fonarow GC, Eagle KA, et al; REACH Investigators. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. *Crit Pathw Cardiol*. 2009;8(3):104–111.
67. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. *JAMA*. 2006;295(16):1912–1920.
68. Holloway RG, Benesch C, Rush SR. Stroke prevention: narrowing the evidence-practice gap. *Neurology*. 2000;54(10):1899–1906.
69. Fox KAA, Steg PG, Eagle KA, et al; GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. *JAMA*. 2007;297(17):1892–1900.